Trevena Inc (TRVN) 6.39 $TRVN
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.39 (+0.12), PTLA: 26.68 (+0.72), ANTH: 3.05 (-0.03), NERV: 11.18 (+0.08)
Trevena to Present at the JMP Life Sciences Conference
BusinessWire - Thu Jun 16, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m. EDT in New York.
TRVN: 6.39 (+0.12)
Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain
BusinessWire - Wed Jun 08, 6:00AM CDT
--- Top-line data for both studies expected in 1Q 2017 -
TRVN: 6.39 (+0.12)
Trevena to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 64.08 (+0.09), TTPH: 4.19 (+0.17), TRVN: 6.39 (+0.12), ADRO: 14.84 (+0.16), ANAC: 99.06 (-0.14)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 64.08 (+0.09), TRVN: 6.39 (+0.12), TTPH: 4.19 (+0.17), VRTX: 98.20 (+1.20), ADRO: 14.84 (+0.16), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14)
Trevena (TRVN) Down on Negative Phase IIb Data on TRV027
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:43AM CDT
Trevena (TRVN) reported disappointing data from a phase IIb study on TRV027, which failed to meet either the primary or secondary endpoints.
TRVN: 6.39 (+0.12), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Apple, Anacor and Tribune Publishing climb, Trevena skids
AP - Mon May 16, 3:21PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
TRVN: 6.39 (+0.12), TPUB: 13.96 (+0.17), MCK: 192.09 (-2.47), PFE: 37.31 (+0.42), MRD: 14.51 (-0.47), TEX: 23.75 (-0.39), ANAC: 99.06 (-0.14), MRO: 12.92 (-0.72), AAPL: 106.05 (+1.84)
Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
BusinessWire - Mon May 16, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs.
TRVN: 6.39 (+0.12)
Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society
BusinessWire - Wed May 11, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.
TRVN: 6.39 (+0.12)
Trevena reports 1Q loss
Automated Insights - Thu May 05, 6:44AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Thursday reported a loss of $17.8 million in its first quarter.
TRVN: 6.39 (+0.12)
Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 6:00AM CDT
--- Oliceridine pivotal Phase 3 efficacy studies expected to begin this quarter -
TRVN: 6.39 (+0.12)
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
BusinessWire - Mon May 02, 3:01PM CDT
--- Phase 3 program includes comparisons to both placebo and morphine -
TRVN: 6.39 (+0.12)
Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
BusinessWire - Fri Apr 15, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Heart Failure 2016 includes the 3rd World Congress on Acute Heart Failure, and is taking place in Florence, Italy, May 21-24, 2016.
TRVN: 6.39 (+0.12)
Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)
Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
BusinessWire - Thu Mar 31, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, being held at The Roosevelt Hotel, 123 Baronne Street, New Orleans, LA from Thursday, March 31, 2016 through Saturday, April 2, 2016. The poster presentations highlight data from the oliceridine program, including key data from the Company's Phase 2b trial in acute pain following abdominoplasty.
TRVN: 6.39 (+0.12)
Trevena Reports Full Year 2015 Financial Results
BusinessWire - Wed Mar 09, 6:00AM CST
--- Net loss for the year of $50.5 million, or $1.15 per share -
TRVN: 6.39 (+0.12)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Trevena to present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Wed Feb 03, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York.
TRVN: 6.39 (+0.12)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.39 (+0.12), PTLA: 26.68 (+0.72), ANTH: 3.05 (-0.03), NERV: 11.18 (+0.08)
Trevena to Present at the JMP Life Sciences Conference
BusinessWire - Thu Jun 16, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m. EDT in New York.
TRVN: 6.39 (+0.12)
Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain
BusinessWire - Wed Jun 08, 6:00AM CDT
--- Top-line data for both studies expected in 1Q 2017 -
TRVN: 6.39 (+0.12)
Trevena to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 64.08 (+0.09), TTPH: 4.19 (+0.17), TRVN: 6.39 (+0.12), ADRO: 14.84 (+0.16), ANAC: 99.06 (-0.14)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 64.08 (+0.09), TRVN: 6.39 (+0.12), TTPH: 4.19 (+0.17), VRTX: 98.20 (+1.20), ADRO: 14.84 (+0.16), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14)
Trevena (TRVN) Down on Negative Phase IIb Data on TRV027
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:43AM CDT
Trevena (TRVN) reported disappointing data from a phase IIb study on TRV027, which failed to meet either the primary or secondary endpoints.
TRVN: 6.39 (+0.12), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Apple, Anacor and Tribune Publishing climb, Trevena skids
AP - Mon May 16, 3:21PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
TRVN: 6.39 (+0.12), TPUB: 13.96 (+0.17), MCK: 192.09 (-2.47), PFE: 37.31 (+0.42), MRD: 14.51 (-0.47), TEX: 23.75 (-0.39), ANAC: 99.06 (-0.14), MRO: 12.92 (-0.72), AAPL: 106.05 (+1.84)
Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
BusinessWire - Mon May 16, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs.
TRVN: 6.39 (+0.12)
Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society
BusinessWire - Wed May 11, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.
TRVN: 6.39 (+0.12)
Trevena reports 1Q loss
Automated Insights - Thu May 05, 6:44AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Thursday reported a loss of $17.8 million in its first quarter.
TRVN: 6.39 (+0.12)
Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 6:00AM CDT
--- Oliceridine pivotal Phase 3 efficacy studies expected to begin this quarter -
TRVN: 6.39 (+0.12)
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
BusinessWire - Mon May 02, 3:01PM CDT
--- Phase 3 program includes comparisons to both placebo and morphine -
TRVN: 6.39 (+0.12)
Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
BusinessWire - Fri Apr 15, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Heart Failure 2016 includes the 3rd World Congress on Acute Heart Failure, and is taking place in Florence, Italy, May 21-24, 2016.
TRVN: 6.39 (+0.12)
Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)
Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
BusinessWire - Thu Mar 31, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, being held at The Roosevelt Hotel, 123 Baronne Street, New Orleans, LA from Thursday, March 31, 2016 through Saturday, April 2, 2016. The poster presentations highlight data from the oliceridine program, including key data from the Company's Phase 2b trial in acute pain following abdominoplasty.
TRVN: 6.39 (+0.12)
Trevena Reports Full Year 2015 Financial Results
BusinessWire - Wed Mar 09, 6:00AM CST
--- Net loss for the year of $50.5 million, or $1.15 per share -
TRVN: 6.39 (+0.12)
Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)
Trevena to present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Wed Feb 03, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York.
TRVN: 6.39 (+0.12)
